CTS delivered a positive second quarter, as evidenced by the strong market reaction following its results. Management credited robust growth in its diversified end markets—including medical, industrial, and aerospace/defense—as the primary drivers of financial performance. CEO Prateek Trivedi emphasized that “robust growth across our diversified end markets drove strong financial results and improved the quality of our earnings despite modest declines in transportation.” The company also noted operational improvements and a more profitable sales mix, while acknowledging one-time items that benefited earnings per share.
Is now the time to buy CTS? Find out in our full research report (it’s free for active Edge members).
CTS (CTS) Q2 CY2026 Highlights:
- Revenue: $144.8 million vs analyst estimates of $143.4 million (7% year-on-year growth, 0.9% beat)
- Adjusted EPS: $0.74 vs analyst estimates of $0.61 (21.3% beat)
- Adjusted EBITDA: $36.8 million vs analyst estimates of $31.46 million (25.4% margin, 17% beat)
- The company slightly lifted its revenue guidance for the full year to $575 million at the midpoint from $570 million
- Management raised its full-year Adjusted EPS guidance to $2.63 at the midpoint, a 9.4% increase
- Operating Margin: 17.4%, in line with the same quarter last year
- Market Capitalization: $1.86 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From CTS’s Q2 Earnings Call
-
John Franzreb (Sidoti & Co.) sought clarity on how new CEO Prateek Trivedi’s approach might differ from his predecessor. Trivedi outlined a focus on accelerating growth in diversified markets while stabilizing transportation.
-
John Franzreb (Sidoti & Co.) asked if the favorable R&D line item was recurring. CFO Ashish Agrawal explained that customer reimbursements can fluctuate but guided toward R&D expenses normalizing in future quarters.
-
John Franzreb (Sidoti & Co.) inquired if medical segment gross margins were higher than other diversified markets. Agrawal confirmed that medical generally carries stronger margins.
-
Hendi Susanto (Gabelli Funds) questioned pricing, cost inflation, and customer negotiations. Agrawal said ongoing discussions with customers and suppliers could yield either cost pressures or pricing benefits, leading to a broad EPS guidance range.
-
John Franzreb (Sidoti & Co.) asked about the commercial vehicle outlook and margin impact. Trivedi and Agrawal described modest growth expectations and noted that gross margins for new transportation programs may be pressured initially before improving over time.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) whether medical and industrial segments sustain their growth trajectory through continued new wins and capacity ramp-up; (2) the pace of aerospace and defense backlog conversion as government funding flows into key programs; and (3) the impact of tariff and cost pressures on transportation margins, particularly as new product launches roll out. Execution on pricing strategies and supply chain negotiations will also be key variables to watch.
CTS currently trades at $65.25, up from $60.41 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
